{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+checkpoint+inhibitor&page=11", "query": { "intervention": "Immune checkpoint inhibitor", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 371, "total_pages": 38, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+checkpoint+inhibitor&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+checkpoint+inhibitor&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T13:19:36.859Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06332131", "title": "Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coronary Microvascular Dysfunction", "Cardiotoxicity", "Breast Cancer", "Lung Cancer (NSCLC)" ], "interventions": [], "intervention_types": [], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2025-01-15", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-15T13:19:36.859Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06332131" }, { "nct_id": "NCT03666273", "title": "Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Bapotulimab (BAY1905254)", "type": "DRUG" }, { "name": "Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2018-09-12", "completion_date": "2024-05-15", "has_results": false, "last_update_posted_date": "2024-05-28", "last_synced_at": "2026-11-15T13:19:36.859Z", "location_count": 8, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03666273" }, { "nct_id": "NCT06819735", "title": "Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "DT-7012", "type": "DRUG" }, { "name": "Immune checkpoint inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Domain Therapeutics Australia Pty Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2025-06-25", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-11-15T13:19:36.859Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06819735" }, { "nct_id": "NCT04179110", "title": "Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transitional Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab and Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-09-18", "completion_date": "2023-06-15", "has_results": false, "last_update_posted_date": "2022-02-22", "last_synced_at": "2026-11-15T13:19:36.859Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04179110" }, { "nct_id": "NCT04840589", "title": "Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Refractory Ovarian Carcinoma" ], "interventions": [ { "name": "BET Bromodomain Inhibitor ZEN-3694", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2022-02-02", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T13:19:36.859Z", "location_count": 9, "location_summary": "Bethesda, Maryland • New York, New York • The Bronx, New York + 3 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840589" }, { "nct_id": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High-risk Muscle Invasive Urothelial Carcinoma" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 915, "start_date": "2026-07-16", "completion_date": "2032-11-23", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-11-15T13:19:36.859Z", "location_count": 19, "location_summary": "Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07720284" }, { "nct_id": "NCT04930055", "title": "Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "COVID-19 Vaccination", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2206, "start_date": "2021-06-30", "completion_date": "2022-03-08", "has_results": false, "last_update_posted_date": "2023-05-19", "last_synced_at": "2026-11-15T13:19:36.859Z", "location_count": 2, "location_summary": "Carmel, Indiana • Indianapolis, Indiana", "locations": [ { "city": "Carmel", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04930055" }, { "nct_id": "NCT07796126", "title": "Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2026-09-30", "completion_date": "2029-05-29", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-11-15T13:19:36.859Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07796126" }, { "nct_id": "NCT03290677", "title": "Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Cryoablation", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-01-17", "completion_date": "2023-11-30", "has_results": false, "last_update_posted_date": "2024-03-18", "last_synced_at": "2026-11-15T13:19:36.859Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03290677" }, { "nct_id": "NCT07250477", "title": "Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer Stage IIIC", "Non-small Cell Lung Cancer Stage IV", "Non Small Cell Lung Cancer", "Non-small Cell Lung Cancer Metastatic", "Non-small Cell Lung Cancer Unresectable" ], "interventions": [ { "name": "Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment.", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2026-01-30", "completion_date": "2036-12", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-15T13:19:36.859Z", "location_count": 4, "location_summary": "Chico, California • Marysville, California • Sacramento, California + 1 more", "locations": [ { "city": "Chico", "state": "California" }, { "city": "Marysville", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Truckee", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07250477" } ] }